First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis - Concepedia

Concepedia

Publication | Open Access

First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

DOI Full Paper Access

160

Citations

34

References

2015

Year

Daniel A. Goldstein, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, Bassel F. El‐Rayes, Christopher R. Flowers

Journal of Clinical Oncology

Abstract

Bevacizumab provides minimal incremental benefit at high incremental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer treatment.

References

	Year	Citations

Page 1